vanilmandelic acid has been researched along with Developmental Disabilities in 1 studies
Vanilmandelic Acid: A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE.
vanillylmandelic acid : An aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid.
Developmental Disabilities: Disorders in which there is a delay in development based on that expected for a given age level or stage of development. These impairments or disabilities originate before age 18, may be expected to continue indefinitely, and constitute a substantial impairment. Biological and nonbiological factors are involved in these disorders. (From American Psychiatric Glossary, 6th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koh, PS | 1 |
| Raffensperger, JG | 1 |
| Berry, S | 1 |
| Larsen, MB | 1 |
| Johnstone, HS | 1 |
| Chou, P | 1 |
| Luck, SR | 1 |
| Hammer, M | 1 |
| Cohn, SL | 1 |
1 trial available for vanilmandelic acid and Developmental Disabilities
| Article | Year |
|---|---|
Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma.
Topics: Abdominal Neoplasms; Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Ataxia; Biomarkers; Child | 1994 |